LungLife AI, Inc.
(the "Company" or "LungLife")
Clinical validation study update
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, provides an update on the Company's clinical validation study for its LungLB® test.
As stated in the Company's half-year report on 8 August 2023, LungLife is currently focussed on preparing data from the clinical validation study for detailed analysis, which was expected to be concluded by the end of September 2023. Due to delays in the provision of data from study sites, full database lock, and the consequent knock-on impact on ability to analyse the data we now expect this to be concluded in Q4 2023.
For further information please contact:
LungLife AI, Inc. | |
Paul Pagano, CEO | Via Walbrook PR |
David Anderson, CFO |
|
|
|
Investec Bank plc (Nominated Adviser & Joint Broker) | Tel: +44 (0)20 7597 5970 |
Virginia Bull / Cameron MacRitchie / Lydia Zychowska | |
| |
Goodbody (Joint Broker) Tom Nicholson / Stephen Kane
| Tel: +44 (0) 20 3841 6202 / +353 (1) 667 0420 |
Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com |
Paul McManus / Alice Woodings / Phillip Marriage | Mob: 07980 541 893 / 07407 804 654 / 07867 984 082 |
About LungLife
LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.